Figure 2: Study procedures

Kidney transplant patients: OGTT > 200mg/dL

Assessment for eligibility

Randomization 32 patients; 1:1

both groups: life style modification

< 2 weeks

Study arm A
16 patients on Vildagliptin

Study arm B
16 patients on Placebo

12 weeks

on study medication (Vildagliptin/Placebo)

no study medication

Primary and secondary endpoint

Secondary endpoint

OGTT, IFG, HbA1c

4 weeks